Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure

Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator. This study evaluated the haemodynamic effect and safety of cinaciguat added to standard therapy in patients with acute decompensated heart failure (ADHF). In this placebo-controlled, phase IIb study (NCT00559650), 139 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal 2013-01, Vol.34 (1), p.57-67
Hauptverfasser:	Erdmann, Erland, Semigran, Marc J, Nieminen, Markku S, Gheorghiade, Mihai, Agrawal, Rahul, Mitrovic, Veselin, Mebazaa, Alexandre
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Benzoates - administration & dosage Benzoates - adverse effects Dose-Response Relationship, Drug Double-Blind Method Early Termination of Clinical Trials Female Glomerular Filtration Rate - drug effects Guanylate Cyclase-Activating Proteins - administration & dosage Guanylate Cyclase-Activating Proteins - adverse effects Heart Failure - drug therapy Heart Failure - physiopathology Hemodynamics - drug effects Humans Hypotension - chemically induced Hypotension - physiopathology Infusions, Intravenous Male Middle Aged Tachycardia, Ventricular - chemically induced Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator. This study evaluated the haemodynamic effect and safety of cinaciguat added to standard therapy in patients with acute decompensated heart failure (ADHF). In this placebo-controlled, phase IIb study (NCT00559650), 139 patients admitted with ADHF, pulmonary capillary wedge pressure (PCWP) ≥18 mmHg, left ventricular ejection fraction
ISSN:	0195-668X 1522-9645
DOI:	10.1093/eurheartj/ehs196